Blarcamesine (ANAVEX 2-73)
Cognitive · Sigma-1 receptor agonist (autophagy)
Tier D+
Bottom line
Read Off Label grades Blarcamesine (ANAVEX 2-73) as D+ (3.7/10) based on weak evidence, low benefit magnitude, and a med-risk safety profile.
Anavex's lead drug — a sigma-1 agonist betting on autophagy enhancement instead of amyloid clearance, which also draws longevity interest since autophagy is a core aging pathway.
Studied, labeled, or reported-use context: Oral once daily; Phase 3 used titrated doses (~30-50 mg/day) — Investigational; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
A sigma-1 receptor agonist targeting autophagy and cellular-stress handling rather than amyloid — a mechanistically distinct bet in a field where the dominant hypothesis has produced modest results. It has completed Phase 2b/3 in Alzheimer's disease.
Why it may not get there
The Phase 2b/3 results were contested: the primary analysis was widely criticised, EMA review was unfavourable, and the effect sizes claimed rest on analytical choices rather than an unambiguous separation. Sigma-1 remains an under-validated target, and the Alzheimer's field has the highest late-stage failure rate in medicine.
What would change this An unambiguous regulatory decision or an independent confirmatory trial.
What the evidence says
Anavex's lead drug — a sigma-1 agonist betting on autophagy enhancement instead of amyloid clearance, which also draws longevity interest since autophagy is a core aging pathway. Phase 2b/3 AD-004 (ATTENTION-AD) in early Alzheimer's showed only modest, subgroup-dependent slowing (greatest in SIGMAR1/COL24A1 wild-type patients) plus a brain-volume signal presented at AD/PD 2026. The EMA's CHMP recommended refusal in Dec 2025 and Anavex withdrew the European application on 25 Mar 2026; the FDA gave NDA-pathway feedback Jan 2026. The autophagy mechanism has attracted consumer interest, while human benefit has been modest and subgroup-dependent and the EMA CHMP recommended refusal. Human efficacy remains disputed and no approval has been granted. A 2026 systematic review in CNS Drugs catalogued the entire clinical evidence base and found how thin it is: one Phase 1 study plus ten reports covering just two randomized trials and their open-label extensions — and of those ten reports, only two are peer-reviewed manuscripts, the rest being two preprints and six conference abstracts. That distribution is itself the finding, and it supports the cautious rating here rather than changing it.
Mechanism
Oral small-molecule sigma-1 receptor (SIGMAR1) agonist that enhances autophagy and cellular homeostasis; aims to slow neurodegeneration rather than clear amyloid
Studied, labeled, or reported dose & route
Oral once daily; Phase 3 used titrated doses (~30-50 mg/day)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Blarcamesine (ANAVEX 2-73)'s effects?
- Read Off Label rates the evidence for Blarcamesine (ANAVEX 2-73) as Weak and the benefit magnitude as low, producing an overall grade of D+ (3.7/10). Anavex's lead drug — a sigma-1 agonist betting on autophagy enhancement instead of amyloid clearance, which also draws longevity interest since autophagy is a core aging pathway.
- What safety findings are reported for Blarcamesine (ANAVEX 2-73)?
- Blarcamesine (ANAVEX 2-73) has a med risk profile in the database. Med (dizziness, confusion at higher doses; long-term safety in dementia populations not established) Legal status: Investigational (EMA MAA withdrawn Mar 2026 after negative opinion; FDA NDA pathway under discussion).
- What doses or routes are reported for Blarcamesine (ANAVEX 2-73)?
- Oral once daily; Phase 3 used titrated doses (~30-50 mg/day) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Blarcamesine (ANAVEX 2-73) work?
- Oral small-molecule sigma-1 receptor (SIGMAR1) agonist that enhances autophagy and cellular homeostasis; aims to slow neurodegeneration rather than clear amyloid
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.